MONTREAL--(BUSINESS WIRE)--Jan. 13, 2006--ATTENTION BUSINESS/FINANCIAL/HEALTH EDITORS. Procyon Biopharma Inc. (TSX:PBP), a biotechnology company developing innovative therapeutics in the fields of cancer and HIV/AIDS, announced today that it has entered into a contribution agreement with National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) under which the Company will receive a contribution of $980,000 for the clinical development of its lead protease inhibitor, PPL-100, for the treatment of drug-resistant HIV.
